COMP <GO>
SBRA vs JPM // FREE CASH FLOW YIELD
Sabra Health Care REIT Inc. (NASDAQ) VS. JPMorgan Chase & Co. (NYSE) • 15-METRIC TALLY: SBRA 5
— JPM 4
▲ FREE CASH FLOW YIELD LEADER: SBRA
LAST: $20.35 (+3.20%) • MKT CAP: $5.04B
fcf-yield
6.96%
LAST: $337.98 (-0.76%) • MKT CAP: $905.33B
fcf-yield
-9.41%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBRA VS. JPM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SBRA | JPM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.50% | 17.72% | -12.22 | JPM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 9.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 6.96% | -9.41% | +16.37 | SBRA | /fcf-yield <GO> |
| Operating Margin | — | 41.98% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 43.60% | 32.48% | +11.12 | SBRA | /net-margins <GO> |
| Revenue Growth (YoY) | 25.40% | 13.23% | +12.17 | SBRA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.78% | 1.95% | +3.83 | SBRA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.37 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | SBRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 4.78% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 53.6 | -0.30 | JPM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.0x | 13.3x | +13.73 | JPM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.04B | $905.33B | -$900.29B | JPM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SBRA REV | JPM REV | SBRA GROSS % | JPM GROSS % | SBRA FCF | JPM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $356.9M | $182.45B | — | — | $348.6M | -$147.78B |
| FY 2024 | $284.6M | $177.56B | — | — | $310.5M | -$42.01B |
| FY 2023 | $236.2M | $158.10B | — | — | $300.6M | $12.97B |
| FY 2022 | — | $128.69B | — | — | — | $107.12B |
| FY 2021 | — | $121.65B | — | — | — | $78.08B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBRA // BETA —
JPM // BETA 1.00